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Dear Editor-in-Chief
More than 5 million Americans are affected by
Alzheimer disease (AD) and by 2050 it is expected
to reach more than 13 million. Numerous studies
have shown that high cholesterol level is a risk
factor for AD (1). Preclinical and human neuropa-
thological studies have clearly shown the correla-
tion between high cholesterol level and Alzheimer
disease incidence. Regarding to epidemiological
studies, a high total cholesterol level in serum of
AD patients has been reported. In a study lower
mental state examination scores were reported in
patients with high levels of total cholesterol or
LDL-C. About three fold total cholesterol level
(odds ratio, 2.8) was reported in AD patients (2).
Patients with AD having high cholesterol or LDL-
C level can experience faster cognitive decline
than those having normal cholesterol measures, as
can those with an APOE-4 allele. Total choles-
terol level has been higher in patients who ulti-
mately have developed mild cognitive impairment
or dementia than in those who did not. Similarly,
high total cholesterol level has substantially in-
creased the risk of dementia (hazard ratio: 1.42)
(3). These findings suggest that high cholesterol
level confers an increased risk in development of
Alzheimer disease. However, the results of some
studies do not confirm this conclusion. Recently
some new warnings, particularly for memory loss,
came as the result of reports published over the
past years, indicating statins cause cognitive impair-
ment (e.g., confusion, memory loss, memory
impairment, forgetfulness and amnesia) (3).
Although the data from the observational studies
and clinical trials do not suggest that cognitive
changes associated with statin use are common or
indisputably lead to clinically significant cognitive
decline, however, this matter and the reports indi-
cating the possible increase in the incidence of
diabetes mellitus which recently were published as
well as other adverse effects of these group of
drugs need more caution to be considered in the
use of these drugs.
It worth mentioning that other than cognitive im-
pairment, 27% increase in diabetes mellitus in
rosuvastatin-treated patients compared to pla-
cebo-treated patients was reported. High-dose of
atorvastatin had also been associated with worsen-
ing glycemic control in atorvastatin users (5). Re-
garding to new reported adverse effects and previ-
ously reported ones, searching for new ways to
control hypercholesterolemia is becoming an ur-
gent. Recently promising results regarding the ef-
fects of herbal medicines in prevention and treat-
ment of hypercholesterolemia (7,8), atherosclero-
sis (9) and other cardiovascular diseases risk fac-
tors (10) have been published. Noteworthy, some
of them other than being anti-hyperlipidemic,
possess anti-diabetic (11) and anti-amnetic (12)
properties. Furthermore, some of these natural
products have been able to reduce hepatotoxicity
(13) and nephrotoxicities (14) of statins and other
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nephrotoxic compounds (15). Therefore, more
investigations about the use of these products as
complimentary or alternative medications for
statins and other lipid regulatory drugs are recom-
mended.
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